

# **CollPlant successfully completed a wound closure clinical study and fully achieved its objective**

**The Vergenix®WD product induced remarkably rapid wound closure and new skin epithelialization, opening the path toward regulatory certifications required for commercialization of CollPlant's products**

- Wound healing annual market size is estimated at billions of dollars and is growing.
- CollPlant's Wound Dressing product ("Vergenix®WD") induced rapid wound closure among diabetes patients, alongside new skin tissue epithelialization.
- At present, CollPlant is already in advanced stages of the CE marking process for the Vergenix®WD and expects to obtain it in the fourth quarter of 2012.

**Rehovot, 7 August 2012, CollPlant (TASE:CLPT)**, developer of products and medical solutions based on human collagen produced via genetic engineering of tobacco plants, announced that it successfully completed a clinical trial using its rhCollagen Vergenix Wound Dressing to treat patients with lower limb ulcer. The objective of the study, which was fully obtained, was to assess the safety and performance of the treatment with Vergenix®WD produced by CollPlant.

**Yehiel Tal, CollPlant's CEO** commented: "We are very satisfied with the results of the study which was completed and whose primary objective was achieved, namely, demonstration of treatment safety. We are particularly satisfied with the healing results, which were excellent and further demonstrated the product's performance. The wound healing market size is estimated at billions of dollars and we aspire to occupy a significant portion of this huge market."

**Tal further commented** "Currently, after successful completion of the trial, we are preparing ourselves toward procuring the regulatory approvals required for marketing recombinant human collagen-based products. Currently, CollPlant is already in advanced stages of the CE marking process for the Vergenix®WD. CollPlant boast a wide spectrum of pipeline products that address many medical disciplines. We are certain that the dressing product will be the pioneer paving the way toward continued development of our other products".

**Dr. Eran Tamir, the principal investigator of the study from Maccabi Health Services** stated "The speed of epithelialization and wound closure was remarkable, when compared to dressings currently in clinical use. Vergenix®WD was also found to promote and accelerate the final wound healing stage, during which wound coverage with new skin takes place".

Within the framework of the study, 16 diabetic patients with lower limb wounds were treated in two Maccabi Healthcare Wound Clinics in Israel. Each patient was treated with the product over the course of two weeks, and was monitored for one week after completion of treatment. The results of the study demonstrated that the healing process following Vergenix®WD treatment was characterized by rapid wound closure, alongside formation of new skin tissue. During and following treatment, no treatment-related side effects, such as inflammation or edema, were recorded, indicating that the Vergenix®WD dressing is safe for human use.

This clinical trial follows comprehensive preclinical program undertaken by CollPlant further confirming the product safety and clinical benefit.

**About the Vergenix®WD Wound Dressing:**

Vergenix®WD is a wound healing dressing, designated to treat, using standard and accepted procedures, acute and chronic wounds, such as burns, pressure sores, venous ulcers, diabetic ulcers, second-degree burns, abrasions, surgical incisions, hemorrhaging wounds and others. Similar products are available, but contain animal- or cadaver-derived collagen. The wound healing market size is estimated billions of dollars and is showing constantly rising trends.<sup>1</sup>

---

<sup>1</sup> Source: "Wound Dressing Market - Global Scenario, Trends, Industry Analysis, Size, Share And Forecast, 2011 - 2017", market report published by Transparency Market Research

**About CollPlant:**

CollPlant is a medical devices firm established in 2004 to focus on advancing regenerative medicine through its cutting-edge technology designed to generate and process proprietary recombinant human collagen, among other patent-protected recombinant proteins. CollPlant is developing a broad spectrum of biomaterials for a wide variety of medical markets, including orthopedics, wound healing, cardiology and general surgery. CollPlant's business model is based on strategic alliances with leading companies toward joint development and marketing of products, alongside in-house development and commercialization of other products and their distribution by third parties.

Disclaimer: The company's plans with regards to CE marking and timetables relating to realization of the aforementioned expected developments, hold true to the date of this release and should be regarded as forward-looking statements as defined by the Securities Exchange Act. All and/or some of these forward-looking statements may not be realized or may be realized in a manner significantly different from that originally expected, which may, in some cases, be due to elements beyond the company's control, including changes in market conditions and the competitive and business environments, trial results that will be performed by the group, regulatory requirements relating to trials conducted by the group, and realization of any of the risk factors applying to the company.

\*\*\*\*\*